Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Waters Corporation  today announced the launch of the BioResolvetm Protein A Affinity Columns with MaxPeaktm Premier Technology, providing precise titer measurements. This launch marks the first set ...

CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with ...

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional ...

The proposed CDR-scanning method starts with known CDR sequences from an already characterized antibody and generates and tests actual antibodies, each having a mutation at one of the CDR residues ...

Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.

The first anti-amyloid monoclonal antibody -- and the first drug of any ... on the 18-point Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over 18 weeks. Mean baseline score was about ...

Subsequent generations, such as CDR-grafted antibodies, see the complementarity-determining regions (CDRs) of a mouse antibody transplanted onto a human framework, further lowering the risk of ...

Of the antibodies currently in trials (green), bepranemab and E2814 ... The trial missed its primary endpoint of improving cognition and function as measured by the CDR-sum of boxes in the full trial ...